We use patient genome-wide gene expression profiling to calculate the specific genes that identify a responding patient population
Demonstrate patient benefit with OakLabs' biomarkers. Improved reimbursement.
OakLabs calculates novel biomarkers to achieve better selectivity than single biomarkers alone that are related to the mechanism of action of the drug and thus yielding higher response rates for drugs in clinical trials and on the market.
If you have any questions or would like to receive more information, please feel free to contact us at any time.
OakLabs, One Broadway, Cambridge, MA 02142, USA
+1 617 - 863 9616